Sagimet Biosciences (STU:0O2) Short Percentage of Float


STU:0O2 Sagimet Biosciences Inc STU:0O2
10 GF Score
Price €6.14
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:0O2 vs EDIT, AUTL, FBRX: Short Percentage of Float Comparison

For the Biotechnology subindustry, Sagimet Biosciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sagimet Biosciences Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's Short Percentage of Float falls into.


STU:0O2
10GF Score
Sagimet Biosciences Inc STU:0O2
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score

Get the complete analysis for STU:0O2

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.14
Price